Clinical Prostate Cancer Research Group

CLINICAL PROSTATE CANCER RESEARCH

Our group is concerned with the identification of markers for therapeutic responsiveness, prognostic markers, and new markers of early prostate disease. We take a multidisciplinary approach that utilises expertise from a number of cancer researchers within and outside the Garvan, as well as clinicians and pathologists. Our research aims to identify genes and pathways whose expression changes can predict the development of aggressive life-threatening prostate cancer or resistance to chemotherapy used for the treatment of advanced stage prostate cancer.

Selected Publications

Mahon KL, Qu W, Lin HM, Spielman C, Cain D, Jacobs C, Stockler MR, Higano CS, de Bono JS, Chi KN, Clark SJ, Horvath LG. Serum free methylated Glutathione S-transferase 1 DNA levels, survival, and response to docetaxel in metastatic, castration-resistant prostate cancer: post hoc analyses of data from a Phase 3 trial. Eur Urol. 2018; in press.

Zhang AY, Grogan JS, Mahon KL, Rasiah K, Sved P, Eisinger DR, Boulas J, Vasilaris A, Henshall SM, Stricker PD, Kench JG, Horvath LG. A prospective multicentre phase III validation study of AZGP1 as a biomarker in localized prostate cancer. Ann Oncol. 2017; 28(8):1903-1909

Mahon KL, Lin HM, Castillo L, Lee BY, Lee-Ng M, Chatfield MD, Chiam K, Breit SN, Brown DA, Molloy MP, Marx GM, Pavlakis N, Boyer MJ, Stockler MR, Daly RJ, Henshall SM, Horvath LG. Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer. Br J Cancer. 2015; 112 (8):1340-1348 

Lee BY, Timpson P, Horvath LG, Daly RJ. FAK signaling in human cancer as a target for therapeutics. Pharmacol Ther. 2015; 146:132-149 

Birch SE, Kench JG, Takano E, Chan P, Chan AL, Chiam K, Veillard AS, Stricker P, Haupt S, Haupt Y, Horvath L, Fox SB. Expression of E6AP and PML predicts for prostate cancer progression and cancer-specific death. Ann Oncol. 2014; 25(12):2392-2397

Galletti G, Matov A, Beltran H, Fontugne J, Miguel Mosquera J, Cheung C, MacDonald TY, Sung M, O'Toole S, Kench JG, Suk Chae S, Kimovski D, Tagawa ST, Nanus DM, Rubin MA, Horvath LG, Giannakakou P, Rickman DS. ERG induces taxane resistance in castration-resistant prostate cancer. Nat Commun. 2014; 5:5548

Mahon KL, Qu W, Devaney J, Paul C, Castillo L, Wykes RJ, Chatfield MD, Boyer MJ, Stockler MR, Marx G, Gurney H, Mallesara G, Molloy PL, Horvath LG, Clark SJ; PRIMe consortium. Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer. Br J Cancer. 2014; 111(9):1802-1809

Lin H-M, Castillo L, Mahon KL, Chiam K, Lee BY, Nguyen Q, Boyer MJ, Stockler MR, Pavlakis N, Marx G, Mallesara G, Gurney H, Clark SJ, Swarbrick A, Daly RJ and Horvath LG (2014). Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. Br J Cancer 110:2462-2471.

Thompson JE, Moses D, Shnier R, Brenner P, Delprado W, Ponsky L, Pulbrook M, Böhm M, Haynes A-M, Hayen A and Stricker PD (2014). Multi-parametric magnetic resonance imaging guiding diagnostic biopsy detects significant prostate cancer, and could reduce unnecessary biopsies and over-detection: a prospective study. J Urol advance online publication 8 Feb 2014.

Lee BY, Hochgrafe F, Lin HM, Castillo L, Wu J, Raftery M, Shreeve SM, Horvath LG and Daly RJ (2014). Phosphoproteomic profiling identifies focal adhesion kinase as a mediator of docetaxel resistance in castrate-resistant prostate cancer. Mol Cancer Ther 13: 190-201.

Thompson JE, Egger S, Böhm M, Haynes A-M, Matthews J, Rasiah K and Stricker PD (2014). Superior quality of life and improved surgical margins are achievable with robotic radical prostatectomy after a long learning curve: a prospective single-surgeon study of 1552 consecutive cases. Eur Urol 65:521-531.

Savdie R, Horvath LG, Pe Benito R, Rasiah KK, Haynes A-M, Chatfield M, Stricker PD, Turner JJ, Delprado W, Henshall SM, Sutherland RL and Kench JG (2012). High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy. BJU Int 109: 1794-800.


More Garvan Publications

Staff in the Group

Dr Amer Amin

Visiting Urology Fellow

Anjali Balakrishnan

Clinical Research Coordinator

Daniela Barreto

Clinical Research Coordinator

Dr Alexander Blazevski

Urology Research Fellow

Andrew Chen

Research Scientist

Thomas Cusick

Visiting Scientist

Andrew Da Silva

Histology Technician

Louise Emmett

Visiting Scientist

Anne-Maree Haynes

Biobank Data Manager

Prof James Kench

Visiting Scientist

Dr Kate Mahon

Clinical Scientist

Blossom Mak

Research Officer

Teah Mazzelli

Blood Processing Technician

Dr Krishan Rasiah

Visiting Scientist

Tahlia Scheinberg

Visiting Student

Matthys Scheltema

Visiting Scientist

Carla Stern

Administrative Director - APCRC

James Symons

Visiting Urologist

Michael Tayao

Blood Processing Technician

Nicole Yeung

Research Assistant

Leeda Zamiri

Blood Processing Technician

Anaiis Zaratzian

Histopathology and Biospecimen Manager